Antiviral | EC50 ratio | Phenotype | Strain | Source | Marker | Assay | Reference |
---|---|---|---|---|---|---|---|
Ganciclovir | 2.60 | Low level resistance | Recombinant | Details | Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024) | ||
Cidofovir | 3.80 | Intermediate level resistance | Recombinant | Details | Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024) | ||
Foscarnet | 1.30 | No resistance | Recombinant | Details | Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024) |
Mutant | Resistances |
---|---|
L501I |
Ganciclovir:
|
L501I |
Cidofovir:
|
L501I |
Foscarnet:
|